666260-76-0Relevant articles and documents
Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain
Giblin, Gerard M. P.,O'Shaughnessy, Celestine T.,Naylor, Alan,Mitchell, William L.,Eatherton, Andrew J.,Slingsby, Brian P.,Rawlings, D. Anthony,Goldsmith, Paul,Brown, Andrew J.,Haslam, Carl P.,Clayton, Nick M.,Wilson, Alex W.,Chessell, Iain P.,Wittington, Andrew R.,Green, Richard
, p. 2597 - 2600 (2008/02/03)
Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X, as the optimal compound in the series. 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clinical candidate for this indication.
PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
-
Page/Page column 32, (2010/02/13)
The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.
PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS
-
Page 40, (2010/02/06)
This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of
